一分钟看懂
这是一项关于神经内分泌癌的II 期研究，登记的药物或干预包括Tarlatamab，当前状态为招募中。登记地点显示中国Taipei有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Tarlatamab · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- National Taiwan University Hospital · Taipei
公开的入选条件
- 1. Written informed consent.
- 2. Failed prior platinum-based chemotherapy
- 3. Histologically proven extrapulmonary small cell carcinoma or neuroendocrine carcinoma from gastrointestinal tract, genitourinary tract, gynecologic origin, and head and neck or unknown primary. When mixed histology (ex, adenocarcinoma, squamous cell carcino
- 4. Measurable lesions by RECIST 1.1 within 28 days prior to the first dose of tarlatamab.
- 5. ECOG Performance Status (PS) of 0 or 1.
- 6. Age greater or equal to 18 years old.
- 7. Subjects willing to provide archived tumor tissue samples (formalin fixed, paraffin embedded \[FFPE\] sample) or willing to undergo pretreatment tumor biopsy.
- 8. Subjects with treated brain metastases are eligible provided they meet the following criteria:
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06816394；登记信息更新于 2026-09-17。